Trials / Completed
CompletedNCT00835237
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,332 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Boostrix® | Intramuscular, single dose. |
| BIOLOGICAL | Decavac™ | Intramuscular, single dose. |
Timeline
- Start date
- 2009-02-17
- Primary completion
- 2009-07-23
- Completion
- 2009-10-15
- First posted
- 2009-02-03
- Last updated
- 2020-01-03
- Results posted
- 2010-08-05
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00835237. Inclusion in this directory is not an endorsement.